Recently, mineralocorticoid receptor antagonists have shown considerable beneficial effects in hypertension [41], heart failure [42], metabolic syndrome [43], chronic kidney disease [44], atherosclerosis [45, 46], and vascular diseases [47]. The gene discussed is NR3C2; the disease is atherosclerosis.